Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
← catalyst calendarNCT07175428 · readout in 174 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Prevention
Enrollment
1,200estimated
Sites
74
Countries
Argentina, Brazil, Canada +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-20 | actual | When the study began enrolling |
| Primary completion | 2027-02-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation (AF)
Interventions
- Drug: REGN7508 — also filed as cenvacibart
- Drug: REGN9933 — also filed as amrecibart
- Drug: Apixaban — also filed as Eliquis
Primary outcome
what the primary-completion date above is the date OFIncidence of any bleeding
measured 12 weeks
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed